In which patients are sulfa medications known to precipitate hemolytic reactions?

In which patients are sulfa medications known to precipitate hemolytic reactions?

• A. Patients with iron deficiency anemia
• B. Patients with vitamin B12 deficiency
• C. Patients with glucose-6-phosphate dehydrogenase deficiency
• D. Patients with thrombocytopenia

Answer: (C)

Sulfa medications can cause hemolytic reactions, particularly in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD is an enzyme that protects red blood cells from oxidative stress. In individuals with G6PD deficiency, certain medications, including sulfonamides, can lead to an increase in oxidative stress, surpassing the red blood cells' ability to cope, thereby resulting in hemolysis. The reaction is due to the formation of reactive oxygen species that damage the red blood cell membrane, leading to their destruction. This susceptibility is rooted in the biochemical pathway that protects red blood cells. Those with G6PD deficiency lack sufficient levels of the enzyme to neutralize oxidative agents, meaning they are at greater risk when exposed to drugs that can induce oxidative stress, such as sulfa drugs. Hence, patients with G6PD deficiency are particularly at risk of experiencing hemolytic reactions when treated with sulfonamides.

Sulfa medications can cause hemolytic reactions, particularly in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD is an enzyme that protects red blood cells from oxidative stress. In individuals with G6PD deficiency, certain medications, including sulfonamides, can lead to an increase in oxidative stress, surpassing the red blood cells' ability to cope, thereby resulting in hemolysis. The reaction is due to the formation of reactive oxygen species that damage the red blood cell membrane, leading to their destruction.

This susceptibility is rooted in the biochemical pathway that protects red blood cells. Those with G6PD deficiency lack sufficient levels of the enzyme to neutralize oxidative agents, meaning they are at greater risk when exposed to drugs that can induce oxidative stress, such as sulfa drugs. Hence, patients with G6PD deficiency are particularly at risk of experiencing hemolytic reactions when treated with sulfonamides.